Novo Nordisk A/S
NYSENVO short interest surges 57% in one week to 22.1M shares, driven by renewed selling pressure on valuation concerns.
A new long-form analysis for NVO this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumThree converging signals on NVO are pointing in the same direction. Short sellers are unwinding positions at pace. Borrowing costs have collapsed. Options traders just flipped to their most bullish stance in a…
Snapshot as of 23 Jun 2026
Novo Nordisk heads into its May 6 Q1 results on the back of a sharp recovery — and with the Street still broadly skeptical about what comes next. The stock has climbed 20% over the past month to $43.88, clawing back a…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NVO — free to start on ORTEX.
Sign up for free →Open NVO on ORTEX